Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

In addition to developing essential packages some DCP3 volumes identify one or more
“augmented” packages that delineate next steps after the essential interventions are …

Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …

Purpose The non–vitamin K antagonist oral anticoagulants (NOACs), dabigatran,
rivaroxaban, and apixaban, provide several advantages over vitamin K antagonists, such as …

Background: More than half of all heart disease and stroke are attributable to hypertension,
which is associated with approximately 10% of direct medical costs globally. Clinical trial …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Background: Direct oral anticoagulants have been developed to address some of the
drawbacks of vitamin-K antagonists. However, special attention should be given when using …

Background: Left atrial appendage closure (LAAC) and nonwarfarin oral anticoagulants
(NOACs) have emerged as safe and effective alternatives to warfarin for stroke prophylaxis …

Background Cost-utility models are frequently used to compare treatments intended to
prevent or delay the onset of cardiovascular events. Most published utilities represent post …

Background. Both ethical and economics concerns have been raised with respect to the
funding of drugs for rare diseases. This article reports both the cost-effectiveness of …